TG Therapeutics Inc (TGTX)
Payables turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue (ttm) | US$ in thousands | 192,785 | 177,271 | 162,242 | 145,863 | 133,962 | 117,671 | 95,647 | 77,570 | 70,111 | 80,019 | 100,664 | 122,043 | 101,520 | 112,914 | 113,311 | 93,728 | 107,850 | 68,247 | 36,265 | 24,547 |
| Payables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue (ttm) ÷ Payables
= $192,785K ÷ $—K
= —
The payables turnover ratio, which is used to measure how efficiently a company manages its trade credit by paying suppliers, for TG Therapeutics Inc is currently not available in the provided data for the period up to December 31, 2024.
The absence of the payables turnover ratio makes it challenging to assess the company's ability to efficiently utilize its accounts payable to support its operations and manage cash flow effectively. Monitoring this ratio over time could provide insight into the company's liquidity management and relationships with suppliers.
As such, without this specific ratio data, a comprehensive analysis of TG Therapeutics Inc's payables turnover performance and its implications for the company's financial health and operational efficiency cannot be provided at this time. Additional financial information is required to evaluate TG Therapeutics Inc's accounts payable turnover effectively.
Peer comparison
Dec 31, 2024